Advancements and New Treatment Options: Optimizing Care for Patients with Graft-vs-Host Disease - Episode 7
Approved Therapies for Steroid-Refractory Chronic GvHD
Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.
